Evidence map›Paper›PMID 36002765›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

TNFAIP3 mediates FGFR1 activation-induced breast cancer angiogenesis by promoting VEGFA expression and secretion.

Mengdi Gao, Xue Li, Mao Yang, WanRu Feng, Yan Lin, Tao He

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mengdi GaoInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Xue LiInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Mao YangInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
WanRu FengInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Yan LinInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China. lydemail@swmu.edu.cn.
Tao HeInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China. hetao198@swmu.edu.cn.ORCID http://orcid.org/0000-0002-1533-0761
Southwest Medical University · CN

Funding

National Natural Science Foundation of China 81572619
6 · The paper itself

Abstract

purposeTo investigate the role and mechanism of TNF-inducible protein 3(TNFAIP3) in breast cancer angiogenesis induced by fibroblast growth factor receptor1 (FGFR1) activation.

methodsThe immunohistochemical assay was used to detect the expression of vascular endothelial cell marker CD31 and CD105 in mice DCIS.COM-iFGFR1 transplanted tumor (previously established by our group). The effects of TNFAIP3 knockout/knockdown breast cancer cell lines on angiogenesis, migration, and invasion of Human Umbilical Vein Endothelial Cells (HUVEC) were detected by the tubulogenesis and Trewells assay. RNA-seq analysis of TNFAIP3 downstreams differential genes after TNFAIP3 knockdown. The expression and secretion of VEGFA after FGFR1 activation in breast cancer cells were detected by qPCR, Western blot, and ELISA.

resultsImmunohistochemistry showed that TNFAIP3 knockout inhibited the expression of CD31 and CD105 in DCIS grafted tumors promoted by FGFR1 activation. Tubulogenesis and Trewells experiments showed that TNFAIP3 gene knockout/knockdown inhibited the angiogenesis, migration, and invasion of HUVEC cells promoted by FGFR1 activation. qPCR assay showed that VEGFA mRNA level in the TNFAIP3 knockdown cell line was significantly down-regulated (p < 0.05). qPCR, Western blot and ELISA results showed that TNFAIP3 gene knockout/knockdown could inhibit the expression and secretion of VEGFA in breast cancer cells induced by FGFR1 activation.

conclusionTNFAIP3 promotes breast cancer angiogenesis induced by FGFR1 activation through the expression and secretion of VEGFA.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingAnimalsCell Line, TumorCell MovementFemaleFibroblast Growth FactorsHumansHuman Umbilical Vein Endothelial CellsMiceNeovascularization, PathologicReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerTumor Necrosis Factor alpha-Induced Protein 3Vascular Endothelial Growth Factor AFGFR1 protein, humanFibroblast Growth FactorsReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerTNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3Vascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisBreast cancerFGFR1TNFAIP3VEGFA

Identifiers

PMID36002765
OpenAlexW4292995264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.